ASLAN Pharmaceuticals (ASLN) in Focus: Stock Moves 7% Higher
ASLAN Pharmaceuticals Limited ASLN was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session.This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $1.4950 to $1.9800 in the past one-month time frame.
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
ASLAN Pharmaceuticalshas a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
ASLAN Pharmaceuticals Ltd. Price
Investors interested in the Medical – Biomedical and Genetics industry may consider Emergent Biosolutions Inc EBS which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.
The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Emergent Biosolutions Inc. (EBS): Free Stock Analysis Report
ASLAN Pharmaceuticals Ltd. (ASLN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.